Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Empagliflozin vs Icosapent Ethyl (Vascepa): they're closely matched on evidence (4.5 vs 4.2/10); they're alternatives for support heart health — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Empagliflozin and Icosapent Ethyl (Vascepa) are closely matched across evidence, studies, and safety.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (1)
Outcomes where both Empagliflozin and Icosapent Ethyl (Vascepa) have evidence — compare verdict strength side-by-side.
Off-label use mirrors approved dosing (10–25 mg once daily in the morning) under a clinician. A prescription drug; not an approved longevity regimen.
morning
Oral tablet (empagliflozin)
Approved dose is 2 g twice daily (4 g/day total) taken with food, under a clinician, for statin-treated adults with elevated triglycerides and high cardiovascular risk. A prescription drug — not a self-directed regimen.
with-meals
Oral capsule — purified EPA ethyl ester (icosapent ethyl)
Months to years
Months to years
Weeks to months
Throughout use
Months to years
Weeks
Weeks to months
Throughout use
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
The New England journal of medicine (2015) · Rct · n=7020
EMPA-REG OUTCOME randomized trial in high-CV-risk type-2 diabetics
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
Circulation (2018) · Rct
Randomized evidence of empagliflozin benefit in established cardiovascular disease
Empagliflozin in Patients with Chronic Kidney Disease.
The New England journal of medicine (2023) · Rct
EMPA-KIDNEY randomized trial in a broad chronic-kidney-disease population
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
The New England journal of medicine (2019) · Rct · n=8179
REDUCE-IT: 8,179 statin-treated patients with elevated triglycerides and high cardiovascular risk
Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT.
Journal of the American College of Cardiology (2019) · Rct · n=8179
REDUCE-IT secondary analysis of total (first plus recurrent) ischemic events
Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the MARINE trial).
The American journal of cardiology (2011) · Rct
MARINE: randomized, placebo-controlled trial in patients with very high triglycerides (≥500 mg/dL)
Both Empagliflozin and Icosapent Ethyl (Vascepa) are closely matched — the best choice depends on your specific health goals.
Both Empagliflozin and Icosapent Ethyl (Vascepa) score equally (72) for support heart health.
No known interactions between Empagliflozin and Icosapent Ethyl (Vascepa) have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.